A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma
EJC Skin Cancer · 2026 · 4 · 100792
DOI: 10.1016/j.ejcskn.2026.100792 ↗Kurz gefasst
Fachartikel in der Zeitschrift EJC Skin Cancer, 2026. Verfasst von J.J. Sacco und 17 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sacco, J., Moser, J., Shoushtari, A., Betof, A., Davar, D., Chandra, S., Ikeguchi, A., Salama, A., Sullivan, R., Khan, S., Patel, S., Joshua, A., Hassel, J., Agbaje-Williams, M., Navarro, M., Marpadga, R., Gullo, G., & Orloff, M. (2026). A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma. EJC Skin Cancer, 4, 100792. https://doi.org/10.1016/j.ejcskn.2026.100792
Vancouver
Sacco J, Moser J, Shoushtari A, Betof A, Davar D, Chandra S, et al. A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma. EJC Skin Cancer. 2026;4:100792. doi:10.1016/j.ejcskn.2026.100792
BibTeX
@article{Sacco2026,
author = {Sacco, J.J. and Moser, J.C. and Shoushtari, A.N. and Betof, A. and Davar, D. and Chandra, S. and Ikeguchi, A. and Salama, A.K. and Sullivan, R.J. and Khan, S. and Patel, S.P. and Joshua, A.M. and Hassel, J.C. and Agbaje-Williams, M. and Navarro, M. and Marpadga, R. and Gullo, G. and Orloff, M.M.},
title = {A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma},
journal = {EJC Skin Cancer},
year = {2026},
volume = {4},
pages = {100792},
doi = {10.1016/j.ejcskn.2026.100792}
}
EUVIMED